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INTRODUCTION
Congestive heart failure (CHF) is a major public
health problem. Nearly 5 million Americans are
afflicted with CHF and about 550,000 new cases are
diagnosed each year (1). CHF is a pathophysiological
condition in which the heart is unable to pump enough
blood to meet the metabolic needs of the body. It is the
endpoint for several cardiovascular diseases including
coronary artery disease, myocardial infarction,
hypertension, cardiomyopathy, congenital heart defects,
myocarditis, and valvular heart disease resulting from
rheumatic fever or endocarditis. Regardless of the
etiology, compensatory and adaptive changes occur in
the heart to preserve cardiac output. Some of these
changes are mediated by enhanced sympathetic nervous
system activity (2). Increased catecholamine outflow
from this system induces sustained elevated activation
of the β-adrenergic receptors (β-ARs), which results in
abnormalities in the β-AR signaling system that may
ultimately lead to the pathogenesis of CHF (3).
In this review, I will discuss (i) β-AR subtypes in
the heart; (ii) the functional role of β-AR signaling in
CHF; and (iii) the recent studies in genetically
engineered mice to elucidate the functional effects and
therapeutic potential of critical genes in the cardiac β-
AR signal transduction pathways.
β-ARs IN THE HEART
The β-ARs belong to the superfamily of membrane
proteins known as G-protein-coupled receptors
(GPCRs) (4). GPCRs are characterized by a conserved
core structure with extracellular amino terminus,
intracellular carboxyl terminus and seven
transmembrane α-helices, which are connected by three
extracellular and three intracellular loops. They
transduce extracellular signals from endogenous
hormones and neurotransmitters, ambient physical and
chemical stimuli, as well as exogenous therapeutic
agents. GPCRs are involved in regulation of a vast array
of physiological processes including sensory
perception, cell growth, metabolism and hormonal
homeostasis.
The transmembrane signaling by GPCRs is initiated
by the binding of ligands such as hormones or
neurotransmitters (Figure 1). Ligand binding induces a
conformational change in GPCRs that causes coupling
with heterotrimeric G-proteins (5). G-proteins consists
of α, β, and γ subunits and GPCR coupling leads to the
exchange of G-protein-bound GDP for GTP and the
dissociation of the G-protein into active Gα and Gβ
subunits to mediate downstream signaling. Based on
their amino acid sequences and function, Gα subunits
are grouped into four subfamilies - Gαs, Gαi, Gαq and
Gα12 (6). Subunits of the diverse G-proteins
differentiate the cellular signal by modulating the
activity of various effector molecules such as adenylyl
cyclase (AC) or phospholipase C-β. These effector
molecules regulate the concentrations of second
messengers in the cell, activating a number of different
downstream signaling molecules.
There are four subtypes of β-ARs-β1-AR, β2-AR, β3-
AR and the β4-AR (6). The β1-AR is found primarily in
the heart and comprises 75-80% of the β-ARs found in
the heart (Figure 2). The β2-AR is expressed in the
lungs, kidneys and blood vessels as well as the heart and
comprises 20-25% of cardiac β-ARs. The β3-AR is
found primarily in the adipose tissue, and minimally in
the heart. The β4-AR is considered a low affinity state
of  β1-AR, which awaits genetic and pharmacologic
characterization. Epinephrine and norepinephrine serve
as the primary agonists for all β-ARs. However, recent
data have revealed significant differences in the
signaling pathways and cellular responses of the β-AR
subtypes (7).
When stimulated, cardiomyocyte β1-AR primarily
binds to the G stimulatory (Gs) protein. The Gα subunit
of the Gs protein (Gαs) activates AC, which generates
the second messenger cyclic adenosine monophosphate
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(cAMP); heightened cAMP levels activate cAMP-
dependent protein kinase A (PKA). Activated PKA then
phosphorylates troponin I, the L-type Ca2+ channel and
phospholamban (PLB), resulting in greater contractility
(8).. In addition to Gs, the β2-AR couples to pertussis
toxin - sensitive G inhibitory (Gi) protein. Gi coupling
releases the activated Giα subunit, which inhibits AC
activity, and the Giβγ subunit, which causes
downstream activation of the mitogen-activated protein
kinases (MAPK). Giα coupling also activates the
cytosolic effector molecule phospholipase A2 (cPLA2),
which causes cAMP-independent enhancement of
calcium signaling and cardiac contraction. Recent
studies indicate that β2-AR-cPLA2 pathway substitutes
for a deficient β1-AR-Gs-cAMP pathway; decreased
β1-AR-AC coupling promotes the β2-AR-cPLA2
pathway, whereas efficient β1-AR-AC coupling
suppresses it by the activity of PKA (9). The effect of
cardiac  β2-AR activation varies depending on the
species, and the developmental or pathophysiological
state of the heart (9). The ability of β-ARs to couple
with different G-proteins allows for the receptors to
activate multiple signaling pathways and initiate diverse
cellular responses.
The β-AR signaling system, like all GPCR systems,
has a number of post-agonist stimulation regulatory
mechanisms that serve to prevent overstimulation (10).
These processes, together known as receptor
desensitization, act as a negative feedback to the β-AR
signal, under conditions of extended agonist
stimulation, by repressing the intensity of β-AR
signaling and decreasing the total number of receptors
in the cell. The first of these processes is the
deactivation of trimeric G-proteins. Soon after the
dissociation of the coupled G-protein into active Gγ and
Gβγ subunits, conformational changes occur that cause
re-formation of the inactive G-protein. The rapid
termination of the G-protein signal maintains the dose-
dependent nature of β-AR signal propagation and resets
the protein for future signaling. Although apparently
contradictory,  β-AR desensitization (discussed later)
much like chronic receptor stimulation, contributes to
the pathogenesis of CHF (3).
Continuous catecholamine stimulation overwhelms
the short-term active/inactive cycling of the G-protein
signal and triggers further negative feedback regulation
of GPCR activity. Activation-dependent regulation of
receptors, also known as homologous desensitization,
proceeds within minutes of agonist stimulation (11).
Homologous desensitization begins when the Gβγ
subunit of the activated G-protein binds with the active
form of a G-protein-coupled receptor kinase (GRK).
GRK2, also known as β-AR kinase 1 (βARK1), is
translocated to the stimulated receptor after binding
with the activated Gβγ subunit, where it phosphorylates
the agonist-occupied β-AR (8). βARK1is the most
prominent cardiac GRK; GRK3 and GRK5, which are
also capable of phosphorylating β-ARs, are present in
cardiac myocytes in minimal levels. Phosphorylation of
the receptor occurs at the C-terminus of the receptor
Figure 1. Classical GPCR signaling. Agonist binding to the receptor results in the coupling with G-proteins and exchange of G-protein-bound
GDP for GTP. The activated G-protein dissociates into Ga and Gbg subunits, both of which independently affect cellular signaling through the
activation or inhibition of effectors such as adenylyl cyclase (AC) or phospholipase C-b (PLC-b). Ga subunits are grouped into four subfamilies
- Gas, Gai, Gaq and Ga12 - based on their structure and function. The members of stimulatory Gas family couple to AC to cause an increase in
intracellular cAMP levels, whereas members of Gai family inhibit AC and decrease cAMP levels. The members of Gaq activate PLC-b,
whereas members of Ga12 family activate Rac and Rho. Gβγ dimers activate large number of effectors including ion channels,
mitogenactivated protein (MAP) kinases and activate or inhibit AC.β-Adrenergic Receptor Signaling 101 Vol. 10  No. 2
protein and targets it for arrestin-induced functional
uncoupling from the G-protein. An alternate
internalization pathway involves phosphorylation of the
receptor protein through the secondary action of a
downstream signaling product of β-AR activation. This
process, known as heterologous desensitization, is
initiated when the second messenger-regulated kinase
PKA phosphorylates the β-AR (12). As opposed to
homologous desensitization, heterologous de-
sensitization indiscriminately phosphorylates both
stimulated and unstimulated receptors. In both cases,
receptor phosphorylation allows for β-arrestin to bind
and interfere with future association with G-proteins,
functionally uncoupling the receptor (13). Binding to β-
arrestin increases the receptor’s affinity for adaptor
protein (AP)-2 and clathrin (14). Internalization of
receptors via clathrin-coated vesicles follows rapidly,
within minutes of stimulation (15).
Following internalization, receptors are transported to
endosomes. At the endosomes, the receptors can be
recycled back to the plasma membrane where they
return to a complete functioning state (14). In response
to persistent receptor stimulation, the internalized
receptor can instead be degraded in the liposome. This
process, known as down-regulation, lowers the total
number of receptors in the cell to relieve chronic
overstimulation. Down-regulation is initiated within
hours to days after consistent receptor internalization.
β-AR SIGNALING IN HEART FAILURE
As the major component of the interface between the
sympathetic nervous system and the cardiovascular
system, the β-AR signaling pathway emerges as a key
actor during the progression of heart failure. Prominent
irregularities in β-AR signaling changes include a
reduction of the β1-AR levels of up to 50%
(interestingly β2-AR levels remain constant), a sharp
increase (up to 200%) of GαI levels, and significantly
elevated βARK1 activity (8). All of these adjustments
reflect severely diminished β-AR signaling, likely the
result of sustained, elevated catecholamine levels.    
Cardiac hypertrophy often directly precedes the onset
of CHF. Excessive stress activates a complex network
of interacting pathways that initiate myocardial
hypertrophy to preserve cardiac function. Conventional
wisdom held that cardiac hypertrophy is an adaptive
process that improves ventricular function in the face of
a growing workload. However, as the cardiac efficiency
of the hypertrophied heart further diminishes, the
sympathetic nervous system is increasingly activated in
an attempt to maintain cardiac output and systemic
blood pressure (16). Furthermore, many studies indicate
that sustained cardiac hypertrophy is closely associated
with reduced contractility and an increased risk of heart
Figure 2. β-AR-mediated cardiomyocyte contractility. Agonist binding stimulates β1-AR and results in coupling with and activation of
heterotrimeric Gs, which dissociates into Gas and Giβγ subunits. The Gas activates both adenylyl cyclase (AC), which increases intracellular
cAMP levels and L-type calcium channel, which allows Ca2+ to enter into cardiomyocytes. The cAMP activates PKA, which phosphorylates (P)
several substrates including phospholamban (PLB), L-type Ca2+ channels, troponin I and the cardiac ryanodine receptor (RyR) resulting in
increased cardiac contractility and relaxation. In addition to Gs, β2-AR couples to pertussis toxin-sensitive Gi upon agonist binding. Activated-Gi
releases Gai subunit, which inhibits AC and Giβγ and activates phospholipase A2 (cPLA2) leading to reduced cardiac contractility. The β1-AR-
induced cAMP suppresses the β2-AR/cPLA2 pathway, via PKA. Asterisks denote activated proteins and        indicates inhibition.102 McGill Journal of Medicine 2007
failure (17). Also, significant desensitization of β-ARs
and other β-AR signaling irregularities are shared
characteristics in the development of cardiac
hypertrophy and the progression of heart failure.
Transgenic mice that lack a hypertrophic response
mechanism suffer less cardiac dysfunction than normal
mice when facing long-term mechanical stress (18). In
light of this evidence, a new paradigm has emerged in
which it is argued that the signaling pathways
stimulated during the hypertrophic process may actually
play a greater role in the pathogenesis of heart failure
than the original stress on the heart. 
According to this model, heightened stimulation by
the sympathetic nervous system elicits a hypertrophic
response in the heart that is initially beneficial but
becomes maladaptive when sustained. The hypertrophic
response causes the activation of a number of signaling
pathways, at a time when consistently elevated
catecholamine levels are already overstimulating the β-
AR signaling pathways. Sustained activation of the β-
AR system combined with biochemical changes
produced by hypertrophic processes strongly activate
desensitization and down-regulation pathways, which
ultimately lead to diminished β-AR function and loss of
contractility.
LESSONS FROM TRANSGENIC MOUSE
MODELS
Over the last decade and a half, cardiovascular
research has been revolutionized through the use of
genetically engineered mouse models. Mouse lines have
been developed to model every aspect of cardiac
pathology. Furthermore, the use of murine α-myosin
heavy chain (αMyHC) gene promoter in ventricular
myocytes has enabled cardiac-specific gene expression.
The αMyHC promoter,which is inactive until around
birth, avoids developmental complications arising from
the specific transgene overexpression (15). The ability
to genetically manipulate molecular components of the
β-AR signaling system in murine heart failure models
provides a powerful experimental system for
uncovering potential roles of various elements of this
system in the pathophysiology of cardiac failure.
β1-AR
The β1-AR has been studied in both gain and loss of
expression studies. β1-AR knockout mice were largely
embryonically lethal, while the surviving mice showed
no response to catecholamine stimulation despite the
presence of β2-ARs (19). Cardiomyocyte-targeted
overexpression of the β1-AR using the αMyHC
promoter generated mice with 5 to 15-fold
overexpression of β1-ARs. The β1-AR overexpressing
mice developed dilated cardiomyopathy and heart
failure at young age, which is similar to the pathology
caused by chronic catecholamine overstimulation (20).
This data reinforced the view that increased β-AR
signaling, as happens in chronic receptor stimulation, is
ultimately detrimental to cardiac function.
β2-AR
Experiments using transgenic mouse models have
made it clear that β1-AR and β2-AR are not identical
signaling molecules. In contrast to β1-AR knockouts,
the  β2-AR knockout mice do not suffer from
developmental defects and show no significant
differences in cardiovascular phenotype when
compared with wild-type mice (21). The β2-AR
knockout mice also differ from β1-AR knockouts in that
they show typical response to catecholamine
stimulation. This indicates that the β1-AR is the
signaling conduit for the catecholamine-induced
changes in cardiac contractility.
Mice with cardiac-specific overexpression of β2-ARs
displayed enhanced basal contractility and cardiac
function with minimal pathology (22). Adenoviral-
mediated gene transfer of β2-AR to myocytes from a
rabbit heart failure model rescued β-AR signaling (23).
Crossing transgenic mice overexpressing moderate
amounts (30-fold above wild-type levels) of cardiac β2-
AR with transgenic mice overexpressing Gαq improved
cardiac function and hypertrophy in the Gαq
overexpression heart failure model (24). These results
are encouraging for the prospective use of β2-AR
overexpression as a therapeutic approach. However,
conflicting data clouded the issue as β2-AR
overexpression has failed to rescue other heart failure
models (25) and has proven deleterious in the face of
pressure overload (26). More information about
appropriate levels of β2-AR expression levels is needed
to clarify the potential therapeutic value of β2-AR gene
transfer.
βARK1
The prevalence of βARK1 activity in the progression
of maladaptive hypertrophy and cardiovascular disease
has made it an object of extensive research. The role of
βARK1was investigated by studying the contrast
between hearts of transgenic mice overexpressing
βARK1 and those expressing a peptide inhibitor of
βARK (βARKct).  βARKct, a peptide expressing the
terminal 194 amino acids of βARK1, contains the Gβγ-
binding domain and competes with endogenous βARK1
for Gβγ subunits necessary for βARK1 activity (27).
Overexpression of βARK1 in transgenic mice showed a
diminished  β-AR response to catecholamine
stimulation. This mirrors the augmented βARK1
activity observed in human heart failure. In stark
contrast, the βARKct mice had enhanced cardiac
function under normal conditions and an augmentedβ-Adrenergic Receptor Signaling 103 Vol. 10  No. 2
response to catecholamine stimulation (28). While
homozygous  βARK1-/- mice were embryonic lethal,
heterozygous βARK1+/- mice had a cardiac phenotype
of enhanced contractility similar to the βARKct
transgenic animals (29, 30).
To determine the significance of increased βARK
activity in the progression of heart failure, a number of
studies were conducted involving the overexpression of
βARKct in mice from various existing heart failure
models. Remarkably, in each case, it was shown that
cardiac overexpression of βARKct leads to prevention
of progressive deterioration in cardiac function,
prevention of hypertrophy, improved exercise tolerance,
and correction of β-AR dysfunction (31). Furthermore,
adenoviral delivery of βARKct to larger animal models
of heart failure has shown therapeutic effects (32).
Taken together, these studies indicate that inhibition of
βARK1 activity can preserve β-AR signaling and lead
to an improved response to catecholamine stimulation.
This suggests that inhibition of βARK1 activity via
introduction of βARKct or other small molecule
inhibitors is a viable therapeutic approach for disease
states characterized by increased βARK1 activity.
It is important to note that the effects of βARK1
inhibition may not be completely relegated to the β-AR
system as βARK1 is involved in a number of non-β-AR
signaling pathways (33). Furthermore, the demonstrated
effectiveness of βARKct expression may not be entirely
attributable to βARK1 inhibition. βARKct functions by
binding to and interfering with activated Gβγ subunits,
so it is very possible that inhibition of alternative Gβγ
pathways contributes to part of the βARKct effect. In
fact, recent evidence has shown that another Gβγ
inhibitor, a N-terminally truncated phosducin, which
acts independently of β1-AR activity, replicates
βARKct’s protective effects (34).
PI3K
Recently, phosphoinositide 3-kinase (PI3K) has begun
to garner interest because of its role at the intersection
of the hypertrophic and β-AR signaling processes.
PI3K, which belongs to a conserved family of lipid
kinases that are involved in the regulation of a variety of
cellular functions including cell growth, survival, signal
transduction and apoptosis, is activated in cardiac
myocytes during the hypertrophic response (35). PI3K
activity is also closely associated with attenuation of β-
AR function resulting in decreased contractility (36,
37). Recent studies demonstrated that βARK1 interacts
with the phosphoinositide kinase (PIK domain) of PI3K
to form a cytosolic complex and facilitates agonist-
mediated PI3K translocation to the plasma membrane
(38). PI3K, via its lipid kinase activity, catalyzes the
production of D-3 phosphoinositides, which recruit
adaptor proteins essential to receptor internalization.
Overexpression of the PIK domain, which
competitively displaces endogenous PI3K and prevents
βARK-PI3K translocation to the membrane,
significantly decreased agonist-stimulated β-AR
internalization. Recently, we demonstrated that
internalization of the receptor also requires the protein
kinase activity of PI3K involving tropomyosin
phosphorylation (39). Furthermore, overexpression of
PI3Kγ, a catalytically inactive mutant, inhibited
agonist-induced β-AR internalization and rescued β-AR
function in calsequestrin overexpressing (CSQ) mice, a
common heart failure model (40). Restoration of β-AR
signaling via PI3Kγ overexpression resulted in
significant improvement in cardiac function and
survival, which indicates that inhibition of membrane-
targeted PI3K represents a novel therapeutic approach
to ameliorate cardiac dysfunction.
CONCLUSIONS AND NEW DIRECTIONS
In recent years, great progress has been made towards
understanding the β-AR system and its role in heart
disease. Increasingly, researchers are viewing the
myocardial hypertrophic response and concurrent β-AR
desensitization as maladaptive responses. However, this
evolving notion is counterintuitive to the successful use
of  β-blockers which favor a reduction of β-AR
stimulation to preserve cardiac function. Understanding
the differences between β1-AR and β2-AR signaling
may explain the apparent effectiveness of these β-
antagonists in restoring β-AR levels and cardiac
function in the failing heart. It is possible that β-
blockers function by inhibiting sustained β1-AR
activity and the associated hypertrophic, pro-apoptotic,
pro-necrotic effects (24). Another possibility is that β-
blockers act to re-sensitize the β-AR system, reversing
the abnormalities in β-AR signaling that result from
prolonged catecholamine stimulation.
Studies using genetically altered mice have identified
Gβγ and PI3K as particularly promising targets for
therapeutic intervention. Further investigation of the
secondary signaling pathways these molecules are
involved in, is needed to fully understand how best to
target these molecules for the treatment of CHF.
Potential approaches include the.use of gene therapy
(with  βARKct or PI3Kγ) or the development of
pharmaceutical inhibitors for heart-specific βARK1 or
PI3K activity.
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